References
- Cantor LB. Brimonidine in the treatment of glaucoma and ocular hypertension. Ther Clin Risk Manag 2006;2:337-46
- Katz LJ; Brimonidine Study Group. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Am J Ophthalmol 1999;127:20-6
- Sall KN, Greff LJ, Johnson-Pratt LR, et al. . Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol. Ophthalmology 2003;110:615-24
- Simmons AT, Earl ML; Alphagan/Xalatan Study Group. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers. Ophthalmology 2002;109:307-15
- Konstas AG, Karabatsas CH, Lallos N, et al. . 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. Ophthalmology 2005;112:603-8
- Netland PA, Mroz M, Rosner SA, et al. . Brimonidine purite and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2003;20:20-30
- Zabriskie N, Netland PA; Brimonidine with Latanoprost Study Groups 1 and 2. Comparison of brimonidine/latanoprost and timolol/dorzolamide: two randomized, double-masked, parallel clinical trials. Adv Ther 2003;20:92-100
- Schuman JS. Antiglaucoma medications: a review of safety and tolerability issues related to their use. Clin Ther 2000;22:167-208
- Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma 2002;11:119-26
- Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther 2001;18:205-15
- Dong JQ, Babusis DM, Welty DF, et al. . Effects of the preservative purite on the bioavailability of brimonidine in the aqueous humor of rabbits. J Ocul Pharmacol Ther 2004;20:285-92
- Cantor LB, Safyan E, Liu CC, Batoosingh AL. Brimonidine-purite 0.1% versus brimonidine-purite 0.15% twice daily in glaucoma or ocular hypertension: a 12-month randomized trial. Curr Med Res Opin 2008;24:2035-43
- Cantor LB, WuDunn D, Catoira-Boyle Y, et al. . Absorption of brimonidine 0.1% and 0.15% ophthalmic solutions in the aqueous humor of cataract patients. J Glaucoma 2008;17:529-34
- Salminen L, Huupponen R. Systemic effects of ocular drugs. Adverse Drug React Acute Poisoning Rev 1989;8:89-96
- Allergan, Data on File, Study Report # PK-02-229
- Schwartz GF, Quigley GF. Adherence and persistence with glaucoma therapy. Surv Ophthalmol 2008;53(Suppl1):S57-68